Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Discover how breast cancer precision oncology using a combination therapy improves survival in advanced PIK3CA-mutated cases.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall ...

HER2 positive/hormone positive vs HER2 positive/hormone negative breast cancer: Clinical presentation, prognosis, and time to relapse—A retrospective cohort study. This is an ASCO Meeting Abstract ...

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, a study has ...

A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further ...

Approximately 70% of breast cancers are HR-positive/HER2 negative. While activating ESR1 mutations are rare at the time of ...

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

Ultrasensitive ctDNA monitoring during CDK4/6 inhibitor therapy for metastatic breast cancer. Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and ...